To prospectively compare the clinical responses and penile color-duplex ultrasound (PCDU) results of oral PDE5 inhibitors (PDE5-Is) with papaverine intracavernosal injection (ICI) and to evaluate whether PDE5-Is could be used as alternatives to vasoactive agent injections, 25 ED patients underwent PCDU three times with an interval of at least 1 week, using different pharmacological induction: ICI mode (30--60 mg papaverine), sildenafil mode (100 mg sildenafil) and tadalafil mode (20 mg tadalafil). The preference of the patients was collected when all tests were completed. No significant differences were found in peak systolic velocity and acceleration time among all three modes. However for the ICI mode, end diastolic velocity of the right cavernosal artery was significantly higher than those of the sildenafil and tadalafil modes 5 min after erection induction, and at 15 min it became lower than those of two PDE5-I modes. Consequently, resistance index of the right cavernosal artery in ICI mode was reversed at 5 and 15 min. In all, 60.0 and 56.0% patients managed to reach full erection in PDE5-Is modes, which was significantly lower than in ICI mode (80.0%). Therefore, although PDE5-Is and papaverine ICI showed similar effects on PCDU parameters in detecting arterial ED, more patients had better clinical responses to ICI, and oral PDE5-Is administration still showed some pitfalls in practical use.
INTRODUCTION
ED has been defined as the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance. 1 It has been suggested that ED may be considered as a clinical manifestation of a generalized vascular disease also affecting the penile arteries. 2 Among all the etiological factors, it was reported that around 30--50% of ED cases are vasculogenic in origin. 3, 4 Intracavernosal injection (ICI) of vasoactive agents plus penile color-duplex ultrasound (PCDU) have been regarded as the most reliable and least invasive evidence-based assessment of ED 5 since Lue introduced this method in 1985. 6 Although ICI is an important method for assessing penile hemodynamics, patients' fear of injection often produces a heightened sympathetic response, which inhibits the response of the cavernous smooth muscle to intracavernous agents. This may produce a false-positive result. 7 In addition, erection induction with vasoactive agents results in several complications, from the common (pain, ecchymosis and penile hematoma) to the most serious (priapism) in up to 7% of cases. 5 On the other hand, PDE5 inhibitors (PDE5-Is), including sildenafil, tadalafil and vardenafil, have become the first-line drug therapies for the treatment of ED. 8 As PDE5-Is are safe, noninvasive and effective in 70--80% cases of ED from various causes, there have been studies concerning the application of PDE-Is in PCDU tests, more specifically, using PDE5-Is as alternatives to vasoactive agent injections. However, the results remain controversial. 9, 10 Moreover, studies have focused on sildenafil 11 and vardenafil. 12 Therefore, the purpose of our study was to prospectively evaluate and compare the clinical responses and PCDU results of oral administration of sildenafil (100 mg) and tadalafil (20 mg) with papaverine ICI and to evaluate whether these PDE5-Is could be used as alternatives to vasoactive agent injections. Also, the differences between these two PDE5-Is were elaborated.
PATIENTS AND METHODS Patients
A total of 25 consecutive patients (age range from 27 to 61 years old, mean 37.3±10.1) were randomly selected from our andrological outpatient department. All the patients enrolled were naive about both the PDE5-I and the ICI approach. All the patients had at least a 3-month history of ED and were excluded from the study if their International Index of Erectile Function-5 (IIEF-5) scores were 421 or if they had any ICI and PDE5-I contraindications such as poor cardiac performance, severe ischemia, coagulation defects, recent myocardial infarction and nitrates or nitric oxide donors taken in any form either regularly or intermittently. The patients underwent complete diagnostic evaluations, including detailed medical and sexual history, physical examination, biochemical (fasting glucose, serum cholesterol, triglycerides, low-and high-density lipoprotein) and hormonal testings (prolactin and total testosterone). Psychological tests (self-rating anxiety scale (SAS) and self-rating depression scale (SDS)) and nocturnal penile tumescence assessment were also performed to determine the psychological status of patients and etiology of ED. The Institutional Review Board of Renji hospital approved the study, and written informed consents were obtained from all the study patients.
Erection induction and ultrasonography
A MyLab 90 Doppler ultrasound diagnostic apparatus (Esaote, Genoa, Italy) and a 10-MHz linear array transducer were used for obtaining real-time images of the corpora cavernosa and for visualization and Doppler calculations of the blood flow in the cavernous arteries. Patients were examined in a quiet, dim room in supine position, with the penis slightly stretched to the abdomen. The transducer was placed on the ventral penile surface and the cavernous arteries were examined at the penoscrotal junction. The Doppler angle was maintained at 601. Peak systolic velocity (PSV), end diastolic velocity (EDV), resistance index (RI) and acceleration time (AT) of bilateral cavernous arteries were recorded. Clinical responses of pharmaco-induced erections were also assessed and recorded.
All the patients underwent clinical response and PCDU tests before and after three modes of pharmacologic stimulus, which are described in detail as follows:
ICI mode: Patients underwent an ICI treatment with papaverine 30--60 mg. An audiovisual sexual stimulus (AVSS) was given to promote penile erection as soon as the injection was given.
Sildenafil mode: Patients were asked to take sildenafil 100 mg 1 h before PCDU. An AVSS was given 15 min before the test, accompanied by selfgenital stimulation.
Tadalafil mode: Patients were asked to take tadalafil 20 mg 2 h before PCDU. Also, an AVSS and self-genital stimulation were performed 15 min before the test.
PCDU tests were performed at 5 and 15 min after the injection (ICI mode) or AVSS (sildenafil and tadalafil modes).
Every patient underwent these three different modes with a washout period of at least 1 week between each mode. The sequence of the modes was determined by a random number table generated by a Visual Basic program (version 8.0, Microsoft, Redmond, WA, USA). Upon completion, patients were asked to fill in a self-made questionnaire about their preferences of these modes. All the PCDU tests were done by the same experienced sonographer, and the same experienced urologist performed all ICIs and clinical assessments.
Main outcome measures
The PCDU criteria for defining a normal erection response included either cavernosal artery PSV X25 cm s À1 or an EDV of o5 cm s
as well as EDV 45 cm s À1 (or/and RI o0.8) were considered as arterial inflow insufficiency; EDV 45 cm s À1 (or with RI o0.8) were considered as venoocclusive dysfunction. Clinical responses were assessed using the erection hardness score. 13 Response options for erections on erection hardness score were as follows: (1) increase in size but not hard, (2) hard but not hard enough for penetration, (3) hard enough for penetration (but not completely hard) and (4) completely hard.
Statistical analysis
Data were expressed as mean ± s.d. when normally distributed, and as median (quartiles) for parameters with non-normal distribution, unless otherwise specified. Comparison of the PCDU parameters and clinical responses among the three modes was performed by using the one-way analysis of variance and Chi-square test, respectively. Differences were considered significant when the P-value was o0.05. Statistical analysis was performed with SAS statistical software (version 8.0, SAS Institute, Cary, NC, USA).
RESULTS
In all the 25 patients, nocturnal penile tumescence assessment showed normal results in 8 (32.0%) and abnormal result in 17 (68.0%), suggesting psychogenic and organic ED, respectively. The characteristics of the sample are summarized in Table 1 . One patient (4.0%) was diagnosed with arterial inflow insufficiency and one patient (4.0%) showed evident signs of veno-occlusive dysfunction. All the remaining 23 patients showed normal hemodynamics, comprising 92.0%. Table 2 shows the PCDU results measured 5 min after erection induction with each of the three modes. EDV of the right cavernosal artery measured in ICI mode was significantly higher than that of sildenafil and tadalafil modes (Po0.05 for both modes). Consequently, RI of the right cavernosal artery measured in ICI mode was significantly lower than that of the sildenafil and tadalafil mode (Po0.05 for both modes). No significant differences were observed in PSV and AT among the three modes in both sides, nor were they found in EDV and RI of the left cavernosal artery. Table 3 shows the PCDU results measured 15 min after erection induction with the three modes. The EDV of the right cavernosal artery measured in ICI mode was significantly lower than that of the sildenafil and tadalafil mode (Po0.05 for both modes). Consequently, RI of the right cavernosal artery measured in ICI mode was significantly higher than those of the sildenafil and tadalafil modes (Po0.05 for both modes). No significant differences were observed in PSV and AT among the three modes in both neither sides, nor were any found in EDV and RI of the left cavernosal artery.
Clinical response assessment using erection hardness score showed that 20 patients (80.0%) achieved a full erection (grade 4) in the ICI mode, whereas in the sildenafil and tadalafil modes, the rates of full erection induction were 15 (60.0%) and 14 (56.0%), respectively. Therefore, the clinical responses to papaverine were significantly better than those to oral sildenafil and tadalafil administration (Po0.05). Table 4 shows the adverse effects secondary to the study drugs. No significant side effect was observed after oral administration of sildenafil and tadalafil. However, two patients (8.0%) in ICI mode required pharmacological detumescence by ICIs due to priapism and 76.0% complained of pain. Also, we have to mention that eight patients (32.0%) had a prolonged erection in ICI mode that lasted 2--3 h after the injection but detumesce without pharmacological treatments.
Concerning patients' preferences of these modes, 12 patients (48.0%) preferred the sildenafil mode and 11 patients (44.0%) preferred the tadalafil mode, which was significantly higher than the ICI mode (2/25, 8.0%). As to their mode preference choices, patients who liked the sildenafil mode or the tadalafil mode mainly reported enough hardness (25% and 18.2%, respectively), painless (50% and 45.5%, respectively) and naturalness (25% and 36.4%, respectively), whereas patients who liked the ICI mode chose enough hardness (50%) and quick response (50%). No other reasons were specified.
Concerning the comparison between sildenafil and tadalafil, no significant differences were found in any of the PCDU parameters. In the clinical response and patients' preferences, no statistical differences were observed. DISCUSSION ICI combined with PCDU provides reliable and detailed information on penile hemodynamics and vascular anatomy and is recommended as a first-line test to evaluate penile arterial and veno-occlusive function. 14, 15 Although most patients with ED can be managed within the primary care setting, some circumstances, such as failure of initial treatment, Peyronie's disease, primary ED and history of pelvic/perineal trauma, require specific diagnostic testings including PCDU. Intracavernous vasodilators and the invasive nature of ICI, however, are known to cause several complications, from common (pain, ecchymosis and penile hematoma) to the most serious (priapism) in up to 7% of cases. In our study, most patients (76.0%) complained of moderate to severe pain and 8.0% had priapism during the ICI mode. Moreover, fears of injections may have caused further anxiety and stress. The increased sympathetic stimulation may result in a false-positive response to pharmacological stimulation and subsequent PCDU results. Shamloul 16 in his study showed that the PSV may be falsely lowered in young ED patients after the first ICI treatment. It was suggested that a repetition of ICI plus a PCDU test should be performed to avoid the influence of these physiological factors. 17 However, it was rarely accepted by the patients in clinics.
Therefore, we tried to investigate the potential of oral sildenafil and tadalafil administration, which has been proven with high effectiveness in promoting erectile responses across a wide spectrum of severity and causes of ED, as the alternative solutions for ICI. Indeed, PDE5-Is differ from papaverine both in molecular structures and mechanism of action. Papaverine increases the production of cyclic adenosine monophosphate and cyclic guanosine monophosphate by an inhibitory action on PDE, although papaverine acts at many levels, leading to a very complex mode of action in the smooth muscle. 18 On the other hand, PDE5-Is maintain an erection by inhibiting the catabolism of cyclic guanosine monophosphate, resulting in increased cyclic guanosine monophosphate. So, the activation of the nitric oxide--cyclic guanosine monophosphate pathway by sexual stimulation is required. Thus, in the absence of sexual stimulation in humans, PDE5-Is has little effect on cavernosal smooth muscle relaxation and does not cause a rigid penile erection. 19 Therefore, we employed an AVSS in our study to facilitate PDE5-Is and make the effects of papaverine and PDE5-Is comparable.
For PSV, the major parameter for diagnosing arterial ED, no significant difference was observed among the three modes in both 5 and 15 min after erection induction. These results indicated that although PCDU with papaverine ICI was accepted as the gold standard, PCDU facilitated with sildenafil or tadalafil could provide similar effects in detecting potential arterial ED.
Secondly, from the aspect of AT, no significant difference was observed among the three modes in both 5 and 15 min after erection induction. ATs of penile arteries have been proposed as an indicator for arterial ED recently. Speel et al. 20 showed a thickened intima media of cavernosal arteries when AT reached X100 ms, which could cause further atherosclerotic ED. Sensitivity For penile color-duplex ultrasound: oral PDE5 inhibitor or ICI? Y Yang et al and specificity were 66% and 71%, respectively. Therefore, our results suggested that oral sildenafil and tadalafil could bring equal presentation of this parameter with a papaverine injection. Although these two parameters were not found to be statistically different, we found that EDV of the right cavernosal artery measured during the ICI mode was significantly higher than that of the sildenafil and tadalafil modes 5 min after erection induction, and at 15 min it became lower than those of two PDE5-I mode. Consequently, RI of the right cavernosal artery measured in the ICI mode changed reversely at 5 and 15 min. These results indicated that PDE5-Is brought a quicker but shorter continuance of erectile response than papaverine ICI. Also, it has been suggested that measurement of PSV for up to 30 min after ICI could improve the diagnostic value of the test. 21 Therefore, if PDE5-Is were to be used as alternatives for papaverine ICI, their characteristic of erection induction should be considered to avoid potential false-positive results.
PDE5-Is and papaverine ICI showed comparable results in the PCDU parameters, but from the respect of clinical response, only 60.0% and 56.0% of patients managed to reach full erection (grade 4) in the sildenafil and tadalafil mode, respectively, which was significantly lower than in the ICI mode (80.0%). In early studies, the association between erection hardness and PSV has been demonstrated. 9 Most patients with erection hardness over grade 3 showed normal PSV, and an insufficient erection would result in falsely lowered PSV. Therefore, oral PDE5-Is failed to bring sufficient clinical response and, thus, may lead to falsepositive results.
Besides, oral PDE5-Is administration still showed some pitfalls in practical use. It was time-consuming and highly dependent on environment, and some patients could not reach sufficient erection with the help of PDE5-Is, but managed to obtain a full erection in the ICI mode. In total, four patients showed this phenomenon. We found some possible explanations after indepth communication with these patients: two patients stated that they were fond of watching erotic films in their spare time and, therefore, did not feel enough sexual stimulation from the AVSS. Another possible reason was the nervousness and anxiety in an unfamiliar environment. Two patients reached an adequately hard erection but became flaccid within 30 s and, therefore, failed the PCDU tests. But they all reported successful erections later after they went back home, suggesting that psychological factors may have a greater impact during the PDE5-Is mode.
Lastly, as to adverse effects, most patients (76.0%) complained about moderate to severe pain and 8.0% had priapism during the ICI mode. Moreover, as mentioned before, significantly more patients had a prolonged erection during the ICI mode that lasted 2--3 h after injection but detumesce without pharmacological treatments. Although this kind of 'prolonged erection' would not cause acidosis or damage to endothelium, unnaturalness and embarrassment were reported when patients returned to work or even walking. That was also the reason why more patients preferred the mixed mode to the ICI mode.
During the past few years, there have been some studies concerning the application of PDE-Is in PCDU tests, but the results remain controversial. Arslan et al. 10 suggested that 50 mg sildenafil administration achieved increased PSV comparably to those after intracavernous papaverine injections, and the sensitivity and selectivity for demonstrating arterial insufficiency were 90% and 100%, respectively. Ardicoglu et al.
12 also supported the idea that 10 mg vardenafil plus genital and AVSS could be used as a safer alternative compared with more invasive ICI. However, there were also studies that showed different opinions. The study by Erdogru et al. 11 indicated that sildenafil citrate plus visual sexual stimulation was not as reliable as ICI and genital sexual stimulation for creating an accurate interpretation of penile vascular status using CDU. Copel et al. 9 also found more patients responded to ICI of the combination of three drugs (papaverine, prostaglandin E1 and phentolamine) than to sildenafil, and the clinical response was significantly better. Moreover, these studies focused on sildenafil and vardenafil. We hope our research could bring some clues for tadalafil and the comparison between PDE5-Is with dissimilar structures (as sildenafil and vardenafil have different structures than tadalafil).
Still, we have to clarify our concerns for the placebo arm. ICI plus PCDU has been recommended as the first-line test to evaluate penile arterial and veno-occlusive function, 15 therefore, the necessity of performing a 'sham injection' was low. Sildenafil and tadalafil were also used to test their effects compared with ICI, which was the main target of our study. Nevertheless, we also believe it would be more valuable if a placebo were added to control the effect of PDE5-Is.
Also, our PCDU results showed only 8% patients with abnormal hemodynamics, and nocturnal penile tumescence test showed 68% abnormalities. The reason behind this might be because of the comorbidities (diabetes mellitus, glycemia, hypogonadism and aging) with enrolled patient (for detailed figures see Table 1 ). Indeed, we have to admit that a more detailed examination regarding neural and testicular function could give a better explanation. However, the vascular status has always been our main concern, and also the main idea of this study.
Potential limits of our study are that comparisons were among the clinical responses and PCDU results of three different modes and no adjustments were made for multiple comparisons. There could be potential shortcomings for false positives. Also, the sample number of participants was relatively small, which restricted further analysis on different age groups and comorbidities.
CONCLUSIONS
In conclusion, PDE5-Is brought a quicker but shorter-lived erectile response than papaverine ICI. Although PDE5-Is and papaverine ICI showed similar effects on the PCDU parameters in detecting arterial ED, more patients had better clinical responses to ICI, and oral PDE5-Is administration still showed some pitfalls in practical use. Therefore, oral administration of sildenafil and tadalafil should still not be used to replace vasodilators injection in PCDU, although with fewer adverse effects and preferred by more patients. Moreover, if PDE5-Is were to be used as alternatives for papaverine ICI, their characteristic of erection induction should be considered to avoid potential false-positive results.
